Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 May;32(5):666-667.
doi: 10.1097/MEG.0000000000001673.

Recurrent 'gloves and socks' distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn's disease

Esin Ozkan  1 , Metin Basaranoglu
Affiliations
Comment

Recurrent 'gloves and socks' distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn's disease

Esin Ozkan et al. Eur J Gastroenterol Hepatol. 2020 May.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, et al.; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss inflammatory bowel disease cohort. Eur J Gastroenterol Hepatol. 2018; 30:612–620
    1. Basaranoglu M, Ertan A, Matthew S, Najjar SM, Ala A, Demirbag AE, et al. Rate and predictors of endoscopic mucosal healing in biologic naive patients with inflammatory bowel disease by azathioprine treatment: a real world, 10 years’ experience from a single center in Turkey. J Gastrointest Dig Syst. 2016; 6:467
    1. Basaranoglu M, Demirkok SS, Coker E. Considerations in seasonal variation studies in IBD and re-evaluation of aratari et al.’s seasonality results. Dig Liver Dis. 2006; 38:710–1; author reply 711
    1. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58:1248–1257
    1. Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohn’s Colitis. 2013; 7:769–779